{"schema_version":"secwatch.filing_event.v1","accession":"0001174947-25-001185","form_type":"8-K","ticker":"CNMD","cik":"0000816956","company_name":"CONMED Corp","filed_at":"2025-09-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.441388+00:00","generated_at":"2026-05-17T07:25:36.290577+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"CONMED appoints Kim Kelderman to Board of Directors effective Sept 8, 2025","bullets":["Kim Kelderman appointed to CONMED's Board, effective September 8, 2025.","He serves on Corporate Governance & Nominating and Strategy Committees.","Kelderman is President & CEO of Bio-Techne (TECH) since February 2024.","Granted prorated equity valued at ~$134,766 (500 RSUs + options for 6,227 shares).","Prior roles include Thermo Fisher Scientific and Becton Dickinson."],"urls":{"canonical":"https://secwatch.observer/filing/0001174947-25-001185","json":"https://secwatch.observer/filing/0001174947-25-001185.json","markdown":"https://secwatch.observer/filing/0001174947-25-001185.md","text":"https://secwatch.observer/filing/0001174947-25-001185.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/816956/000117494725001185/0001174947-25-001185-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/816956/000117494725001185/form8k-34670_cnmd.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T07:25:36.290577+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}